The FDA have a threshold effect on glycemic markers like HPA1C for new drugs that are targeted at Type 2 diabetics. And it's got to be an impact of over 0.3%. For me to have a drug that goes through further development, I've got to demonstrate that my drug can drop your HPA1c by at least 0.3% In this meta-analysis, they found that using one of those different types of fibosupplements, so Cilium, BTB, and conjugate and guagam, reduced HPA 1C by 0.58%. So almost double the amount that the FDA recommend or have as a threshold before

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode